Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule ...
Kura Oncology公布有前景的临床前数据
Investing.com — Kura Oncology, Inc. (NASDAQ: KURA )，一家市值5.75亿美元的临床阶段生物制药公司，宣布其关于KO-2806的临床前数据摘要已被美国癌症研究协会 (AACR)年会接受进行口头报告。根据 InvestingPro 分析，该公司在当前水平上似乎被低估，分析师设定的目标价格在每股10美元至40美元之间。该演讲计划于2025年4月28日进行 ...